Medicare AdvantageCoverageMedium impact
MA11.055g, Procedures for the Treatment of Gastroesophageal Reflux Disease (GERD)
Independence Blue Cross·Gastroenterology, General Surgery·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued MA11.055g effective 01/01/2026 with minor updates to GERD procedure coverage criteria. Six new CPT codes (1013T-1018T) were added as experimental/investigational, making them non-covered. Covered procedures include surgical fundoplication, magnetic esophageal ring implantation (LINX), and transoral incisionless fundoplication (TIF) when medical necessity criteria are met.
Action Required
Before 01/01/2026: Billing team must update claims processing system to recognize new CPT codes 1013T, 1014T, 1015T, 1016T, 1017T, and 1018T as experimental/investigational and non-covered services for Medicare Advantage members. Implement edits to deny or route claims with these codes for manual review. Ensure billing staff understands that covered GERD procedures require documented medical necessity per policy criteria (fundoplication: failed medical management or comorbidities; LINX device: chronic GERD ≥2x/week, failed PPI therapy ≥6 months, proven GERD by endoscopy/pH monitoring, adequate peristalsis, no contraindications). Train providers and staff on contraindications for LINX implantation (metal allergies, hiatal hernia >3cm, Barrett esophagus, dysphagia >1x/week, BMI >35, age <21, pregnancy/lactation). Update encounter forms and templates to require documentation of medical necessity criteria. Flag claims lacking required documentation for denial.